• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

    5.390 -0.340 (-5.93%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 827,751
    Open 5.680
    Bid (Size) 5.320 (800)
    Ask (Size) 5.450 (5,000)
    Prev. Close 5.730
    Today's Range 5.360 - 5.680
    52wk Range 5.360 - 13.67
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 60.6% below 52-week high
    5.390
    5.3652W Low 13.6752W High
    1 Week 14.4% below 1-week high
    5.361W Low 6.301W High

    Kyverna Therapeutics, Inc. - Common Stock (KYTX) traded between $5.36 and $13.67 over the past 52 weeks and last traded at $5.39, 60.6% below its 52-week high. Over the past week it ranged between $5.36 and $6.30.

    Past 12 Months
    -7.5%
    -23.8%
    -27.3%
    -40.5%
    -38.5%
    -15.8%
    1W -$0.44
    1M -$1.68
    3M -$2.02
    6M -$3.67
    YTD -$3.38
    1Y -$1.01

    KYTX was -15.8% over the past year, -40.5% over six months, -38.5% year to date, -7.5% in the last week.

    12 Months vs Market
    KYTX
    -15.8%
    DIA
    +11.6%
    SPY
    +13.1%
    QQQ
    +15.4%
    IWM
    +11.9%

    Over the past 12 months KYTX returned -15.8% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

    Volume & Liquidity 0.99× 3-mo avg
    Today 827,751 3-mo avg 835.0K
    1W
    756.1K
    1M
    998.8K
    3M
    835.0K
    6M
    945.2K
    YTD
    914.0K
    1Y
    1.0M

    KYTX most recently traded 827,751 shares against a 3-month average daily volume of 835.0K.

    More News

    Read More
    News headline image
    Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Present at Upcoming Investor Conferences
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    News headline image
    Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Present at Upcoming Investor Conferences
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Wednesday? ↗
    Via Chartmill
    News headline image
    Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
    Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
    The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
    What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
    The current price of Kyverna Therapeutics, Inc. - Common Stock is 5.390
    When was Kyverna Therapeutics, Inc. - Common Stock last traded?
    The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.